Trial · NCT01360554
Results by group100
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 100
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-Free Survival (PFS) Per Independent Radiologic Review. | Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo) | 2.6 | 95% Confidence Interval 1.9 to 2.8 | Months | |
| Progression-Free Survival (PFS) Per Independent Radiologic Review. | Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo) | 2.5 | 95% Confidence Interval 1.9 to 2.8 | Months | |
| Progression-Free Survival (PFS) Per Independent Radiologic Review in KRAS Wild-type (WT) Participants. | Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo) | 2.6 | 95% Confidence Interval 1.9 to 2.9 | Months | |
| Progression-Free Survival (PFS) Per Independent Radiologic Review in KRAS Wild-type (WT) Participants. | Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo) | 2.5 | 95% Confidence Interval 1.9 to 3.0 | Months | |
| PFS Based on Investigator Review. | Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo) | 1.9 | 95% Confidence Interval 1.9 to 2.6 | Months | |
| PFS Based on Investigator Review. | Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo) | 1.9 | 95% Confidence Interval 1.8 to 2.1 | Months | |
| PFS Based on Investigator Review in KRAS-WT Participants. | Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo) | 1.9 | 95% Confidence Interval 1.8 to 2.7 | Months | |
| PFS Based on Investigator Review in KRAS-WT Participants. | Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo) | 1.9 | 95% Confidence Interval 1.8 to 2.6 | Months | |
| Overall Survival (OS). | Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo) | 7.9 | 95% Confidence Interval 6.8 to 9.0 | Months | |
| Overall Survival (OS). | Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo) | 8.3 | 95% Confidence Interval 7.4 to 9.7 | Months | |
| OS in KRAS-WT Participants. | Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo) | 8.1 | 95% Confidence Interval 6.7 to 9.4 | Months | |
| OS in KRAS-WT Participants. | Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo) | 8.5 | 95% Confidence Interval 7.5 to 10.2 | Months | |
| Best Overall Response (BOR) Per Independent Radiologic Review. | Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo) | Complete response | 6 | Participants | |
| Best Overall Response (BOR) Per Independent Radiologic Review. | Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo) | Complete response | 8 | Participants | |
| Best Overall Response (BOR) Per Independent Radiologic Review. | Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo) | Partial response | 46 | Participants | |
| Best Overall Response (BOR) Per Independent Radiologic Review. | Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo) | Partial response | 27 | Participants | |
| Best Overall Response (BOR) Per Independent Radiologic Review. | Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo) | Stable/No response | 163 | Participants | |
| Best Overall Response (BOR) Per Independent Radiologic Review. | Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo) | Stable/No response | 182 | Participants | |
| Best Overall Response (BOR) Per Independent Radiologic Review. | Arm A (Blinded Dacomitinib and Blinded Erlotinib Placebo) | Objective progression | 151 | Participants | |
| Best Overall Response (BOR) Per Independent Radiologic Review. | Arm B (Blinded Erlotinib and Blinded Dacomitinib Placebo) | Objective progression | 146 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01360554/results